Pharma BD Deal Intelligence
Value created via Teva divestiture and Botox growth but entity sold to AbbVie for $63B
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Actavis acquired Allergan for approximately $70.5 billion in a cash-and-stock transaction, combining Actavis's generics scale with Allergan's branded specialty portfolio anchored by Botox. The combined company adopted the Allergan name post-close.
Value created via Teva divestiture and Botox growth but entity sold to AbbVie for $63B
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Actavis plc / Allergan plc (this deal) | 2014 | $70.5B | 61 |
| Actavis plc / Forest Laboratories, Inc. | 2014 | $25.0B | 75 |
| Actavis plc / Warner Chilcott plc | 2013 | $8.5B | 63 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
← Browse all deals · How we score deals
More: 2014 deals · Actavis plc deals · Gastroenterology deals